BPC-157 oral vs injection: what was studied

No published human study has given BPC-157 as an oral capsule or as an injection under the skin, so nobody knows whether one form works better or is safer than the other. Rats received it by mouth and by injection; the five small human studies the FDA found used an enema, a knee injection, a bladder injection and an IV drip, which are not the forms sold today.

BPC-157 is not approved anywhere, and this page compares what was studied, not what to take. If you’re checking the arithmetic on a vial label, the reconstitution calculator works out concentration from the mg and water you enter; it doesn’t choose an amount.

The forms on the market

The FDA’s briefing for its July 2026 advisory meeting says BPC-157 products “are marketed as an oral capsule, oral spray, nasal spray, and injectable product.” The nominations asking the FDA to allow it in compounding named two of those: an oral capsule and an injection under the skin (subcutaneous, or SC). None is an approved medicine: “There is no approved product containing BPC-157-related BDSs in any country at this time,” and BPC-157 is in none of the European, Japanese or International Pharmacopeias (FDA briefing, sections I and III).

Route by route

What the FDA’s review and the primary papers report, by how the peptide was given. Study amounts are left out on purpose.

Sources: FDA briefing sections II.D.1 and II.D.2; knee review; bladder pilot; IV pilot; ClinicalTrials.gov.

The FDA’s summary of the five human studies: “No serious adverse events appear to have been reported with these studies. However, these studies were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data.” None of the knee, bladder or IV reports had a placebo group.

Absorption: what’s known and what isn’t

• Stomach acid. “BPC-157 was reported to be resistant to hydrolysis in gastric juice in vitro,” which is a lab-dish finding, not a measurement in people (FDA briefing, section II.D.1.b).
• Oral and SC uptake. How much reaches the blood by mouth, under the skin, through the nose or through the skin “to rats or dogs is unknown,” and the FDA found no human data for any of those routes (FDA briefing).
• Enema. In the two enema studies, “BPC-157 was not detected in plasma samples,” and the FDA concluded “it does not appear that BPC-157 is absorbed systemically when given as a rectal enema.”
• Injection into muscle, in animals. A 2022 study measured absolute bioavailability of “approximately 14%-19% in rats and 45%-51% in beagle dogs” (He et al., 2022).
• Half-life, in animals. After a single IV dose, the half-life ranged “from 5.3 minutes in dogs to 15.2 minutes in rats.” The FDA says the short half-life is “likely due to its hydrolysis catalyzed by blood- and/or tissue-specific peptidases.”

So the honest answer to “what is BPC-157’s oral bioavailability?” is that it’s unknown: the FDA found no study that measured it, in animals or people.

Risks that depend on the route

Immune reactions. The FDA says the risk of the body reacting to a peptide “may be enhanced when peptides are given via SC or nasal ROA. In general, SC and nasal ROA is associated with increased immunogenicity compared to oral or rectal ROA.” Possible reactions “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions” (FDA briefing, section II.D.2.d).

Quality risks don’t stop at injections. The same section says that “although inherent immunogenic risk for BPC-157 administered orally is likely to be low, FDA is concerned about the other risks related to peptides,” such as peptide-related impurities. The FDA found data “lacking or deemed to be inadequate” on impurities, aggregates and microbial quality for each dosage form, “(e.g., injection, metered-dose spray solution, capsule, topical cream, suppository).” It added that the stability, activity and immune properties of peptides “are highly sensitive to the manufacturing process” (FDA briefing, section III.1).

Adverse event reports. The FDA’s FAERS database held three BPC-157 reports through December 4, 2025, and “All reports were associated with injectable BPC-157”: injection-site redness and swelling, shortness of breath leading to an emergency visit, and skin and gum darkening with a two-peptide product. Three reports are too few to compare routes, and the FDA notes that “Compounders under section 503A of the FD&C Act generally do not report adverse events to FDA.”

What the FDA concluded

The FDA lists BPC-157 among nominations withdrawn from its Category 2 safety-risk list, with this note: “FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans” (FDA, content current as of April 22, 2026).

For the July 2026 advisory committee, FDA staff proposed “not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List,” citing poor characterization, “a lack of information on the safety profile and immunogenicity risks” and “insufficient evidence to make a conclusion on the effectiveness.” The only use it could evaluate was ulcerative colitis, and it “did not identify any studies that administered BPC-157 via the oral, SC, nasal, or transdermal ROA in subjects with UC” (FDA briefing).

On July 23, 2026, the committee narrowly voted to recommend adding BPC-157 to the list, although FDA staff had unanimously opposed adding any of the peptides under review (ABC News, 2026). The FDA notes that “Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so” (FDA). As of October 16, 2026, the FDA had published no proposed or final rule on BPC-157; that rulemaking step “can take up to a year” (ABC News, 2026). For what happens next, see the BPC-157 page and peptide regulation.

Sport: the form doesn’t matter

WADA’s 2026 Prohibited List names BPC-157 under S0, non-approved substances, “prohibited at all times” in and out of competition (WADA). The list names the substance, not a route, so a capsule is covered as much as an injection. Anti-doping scientists have studied how BPC-157 breaks down in human plasma “for purposes of anti-doping screening” (FDA briefing).

Trials that may change the picture

• Under the skin, hamstring strain: a phase 2, placebo-controlled trial of 120 people in China, recruiting since February 2, 2026, with primary completion estimated for February 14, 2027 (NCT07437547).
• Rotator cuff surgery: a phase 1 trial of 30 people at the University of Arkansas, comparing BPC-157 with a no-treatment group, not yet recruiting, with a planned start of January 1, 2027 (NCT07803250).
• By mouth: the only oral trial registered before 2026 is a phase 1 oral-tablet study in healthy volunteers in Mexico, started in October 2015. Its registry status is “unknown,” and the FDA wrote: “we were unable to find an associated published study” (NCT02637284).

A 2025 review sums it up: “Until well-designed clinical trials are conducted, BPC-157 should be considered investigational” (McGuire et al., 2025).

Questions people ask